Skip to content

Takeda Pharmaceutical

US · TAK #400 by market cap Listed 1970
21.77 +0.36 +1.68%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 21.91 +2.32%
After-hours 22.09 +1.47%
Overnight 21.86 +2.10%
21.7715.0321.772026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on TAK?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +38.8% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Analyst tilt is Buy.
Quant Technical Outlook Bullish
  • Price is above its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days B → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall C-

The radar needs all six factors. Available grades are shown below.

Valuation D-

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 311.0x Better than 1%
Forward P/E 39.3x Better than 11%
Price / Sales 2.3x Better than 52%
P/E vs own 5-yr range 100th pctl Better than 1%
Growth C+

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 3.8% Better than 42%
Net income CAGR (3Y) -22.3% Better than 16%
Free cash flow CAGR (3Y) 22.2% Better than 67%
Profitability C+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 65.1% Better than 79%
Operating margin 10.3% Better than 52%
Net margin -3.4% Better than 21%
Return on equity -2.1% Better than 26%
Return on invested capital -0.6% Better than 27%
Momentum A+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 19.7% Better than 96%
6-month return 34.0% Better than 91%
12-month return (ex latest month) 44.0% Better than 80%
Distance below 52-week high 1.3% Better than 99%
Financial Health C+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 1.1x Better than 24%
Debt to assets 31.5% Better than 39%
Interest coverage 0.0x Better than 25%
Free cash flow / net income 627.8% Better than 94%
Analyst View N/A

What the Street thinks: share of Buy ratings and upside to the average target.

Not enough data to grade this factor.

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W +1.59%
1M +8.42%
3M +20.08%
6M +30.52%
YTD +42.04%
1Y +57.49%
3Y +72.64%
5Y +79.54%

Key statistics

Price & volume

Prev close
21.41
Open
21.82
Day range
21.74 - 22.07
Avg price
21.87
Volume
3.80M
Turnover
83.19M
Amplitude
1.52%
52-week range
13.92 - 22.07

Valuation

P/E
-71.85
P/E (TTM)
311.00
P/B
1.50
EPS
-0.30
Net profit
-970.94M
Net assets
46.44B

Share structure

Market cap
69.76B
Float cap
67.54B
Shares out
3.20B

Dividend & listing

Dividend (TTM)
0.31
Listing date
1970-01-01
52-week range 96% of range
13.92 22.07

1.3% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+3.04M net over the window

Short interest

Shares short
3.07M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Takeda Pharmaceutical (TAK)?

Takeda Pharmaceutical last traded at 21.77. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Takeda Pharmaceutical's market cap?

About 69.76B.

What is the P/E ratio of Takeda Pharmaceutical?

The trailing twelve-month P/E is 311.00, above its own 5-year average of 40.04 — toward the top of its historical range (100.00% percentile). See the Valuation tab for the full history.

Does Takeda Pharmaceutical pay a dividend?

Yes. The trailing dividend yield is 1.44%. The 2025 payout was up 6.9% from 2024. See the Dividends tab for the full payment history.

Is Takeda Pharmaceutical a buy according to analysts?

The consensus of 1 analysts is a Buy rating, with an average 12-month price target of 50.46, which implies 131.8% upside from the current price. This is not investment advice.

What is Takeda Pharmaceutical's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Takeda Pharmaceutical a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.

Takeda Pharmaceutical discussion 0 comments

Add a comment